The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized Study
Open Access
- 15 September 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (6), 715-722
- https://doi.org/10.1086/520983
Abstract
Background. A 9-month course of isoniazid monotherapy is currently recommended for the treatment of latent tuberculosis infection (LTBI) and has been shown to be effective in both children and adults. Reduced compliance with this regimen has forced physicians to explore shorter regimens. The aim of this study was to compare 3- and 4-month combination regimens of isoniazid plus rifampin with a 9-month regimen of isoniazid monotherapy for the treatment of LTBI in children. Methods. This prospective, randomized, controlled study was conducted over an 11-year period (1995–2005). In period 1 (1995–1998), 232 patients received isoniazid therapy for 9 months (group A), and 238 patients received isoniazid and rifampin for 4 months (group B). In period 2 (1999–2002), 236 patients were treated with isoniazid and rifampin for 4 months (group C), and 220 patients received the same regimen for 3 months (group D). All patients were observed for ⩾3 years. Results. Overall compliance with treatment was good, but patients who received isoniazid monotherapy were less compliant than were those who received short-course combination therapy (P = .011, for group A vs. group B; P = .510, for group C vs. group D). No patient in any group developed clinical disease during the follow-up period. New radiographic findings suggestive of possible active disease were more common in patients who received isoniazid monotherapy (24%) than in those treated with shorter regimens (11.8%, 13.6%, and 11% for groups B, C, and D, respectively; P = .001 for group A vs. group B; P = .418 for group C vs. group D). Serious drug-related adverse effects were not detected. Conclusions. Short-course treatment with isoniazid and rifampin for 3–4 months is safe and seems to be superior to a 9-month course of isoniazid monotherapy.This publication has 30 references indexed in Scilit:
- Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from childrenEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- Adherence to isoniazid preventive chemotherapy: a prospective community based studyArchives of Disease in Childhood, 2006
- Childhood drug-resistant tuberculosis in the Western Cape Province of South AfricaActa Paediatrica, 2006
- Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysisClinical Infectious Diseases, 2005
- Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and AdolescentsPEDIATRICS, 2004
- Follow‐up of compliance with tuberculosis treatment in children: Monitoring by urine testsPediatric Pulmonology, 2003
- Mycobacterial Cervical Lymphadenitis in Children: Clinical and Laboratory Factors of Importance for Differential DiagnosisScandinavian Journal of Infectious Diseases, 2001
- Treatment of Latent Tuberculosis Infection: Renewed Opportunity for Tuberculosis ControlClinical Infectious Diseases, 2000
- Resurgence of tuberculosis in childrenThe Journal of Pediatrics, 1992
- Multidrug therapy for tuberculosis in childrenThe Pediatric Infectious Disease Journal, 1990